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Prevalence of hypersensitivity to non-steroidal anti-inflammatory
drugs (NSAIDs) in the population of adult asthmatics in Poland
based on an epidemiological questionnaire
Abstract
Introduction: Hypersensitivity reactions to drugs account for 25% of all side effects related to drugs, affecting more than 7%
of the population. One in four such reactions is caused by acetylic acid and other non-steroidal anti-inflammatory drugs.
Material and methods: Between 1998 and 2000 epidemiological research was carried out in various centers, with the aim of
estimating the frequency of allergy-based diseases in Poland. The objective of the study was to evaluate the frequency of hypersensi-
tivity to non-steroidal anti-inflammatory drugs (NSAIDs), based on an epidemiological questionnaire, in the Polish adult population.
Results: Bronchial asthma was diagnosed in 582 patients (5.4%). Of that group, 75 patients (12.9%) additionally reported
symptoms of hypersensitivity to NSAIDs. Aspirin-induced asthma was diagnosed in 11 patients (14.7%) with clinical
manifestations of hypersensitivity responses. Frequency of aspirin-induced asthma with clinical symptoms amounted to
1.9% of asthmatics. In the assessment of severity of the disease, aspirin intolerance was the only statistically significant
factor (p = 0.0003; odds ratio 28.6 with assumed 95% confidence interval).
Conclusions: In the population of adults in Poland, the frequency of aspirin-induced asthma amounted to 0.1%. Hypersensi-
tivity to NSAIDs was observed in 12.9% of asthmatics. In asthmatics with symptoms of hypersensitivity to non-steroidal
anti-inflammatory drugs, which takes the course of clinically demonstrable aspirin-induced asthma, the risk of severe
asthma is 30-fold higher.
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Introduction
Hypersensitivity reactions to drugs account for
about 25% of all side effects related to drugs, af-
fecting more than 7% of the population [1]. It has
been discovered that one in four of such reactions
is caused by acetylic acid and other non-steroidal
anti-inflammatory drugs [2].
Like many other drugs, aspirin and non-ste-
roidal anti-inflammatory drugs may lead to hyper-
sensitivity reactions, which can be either related
or unrelated to the mechanism of immunological
response [3]. In 2001 Stevenson [4] and the Euro-
pean Academy of Allergology and Clinical Im-
munology published the clinical classification of
hypersensitivity reactions to aspirin and NSAIDs.
Eight reaction types were distinguished, the first
four being related to the suppression of the activi-
ty of cyclooxygenase (an important enzyme in the
metabolism of arachidonic acid) by aspirin and
other non-steroidal anti-inflammatory drugs. The
other four reactions are peculiar and characteristic
of a given drug substance. They probably occur in
the immunological pathway, regardless of cyclo-
oxygenase inhibition. The first two reaction types
are most common in clinical practice.
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The first one relates only to asthma patients,
who may often be affected by chronic sinusitis and
nasal polyps. Following the administration of aspi-
rin and other non-steroidal anti-inflammatory
drugs, these patients experience attacks of asthma,
chronic inflammation of the nasal mucosa, redde-
ning of the eyes and face, and oedema of soft tis-
sue around the eyes. Some patients may only have
symptoms in the lower airways, while in others the
symptoms may affect the upper airways, i.e. the
nose, sinuses and eyes. Such a clinical form of the
condition is referred to as aspirin-induced asthma
[5–8]. In some cases patients may also suffer from
ailments in the gastrointestinal tract and have skin
problems. The reaction of the first type is brought
about by aspirin as well as other non-steroidal anti-
inflammatory drugs that are capable of inhibiting
cyclooxygenase. The reaction of the second type
concerns the skin. From 15 minutes to two hours
after taking aspirin, and/or other NSAIDs, some
patients with chronic idiopathic urticaria develop
urticaric wheals on the face, the hairy parts of the
head, neck and upper chest. It is often accompa-
nied by angioedema. These reactions depend on
the drug dose taken by the patient and also on the
intensity of chronic urticaria symptoms. The more
aggravated the symptoms, the greater the likeliho-
od that aspirin-induced symptoms will appear and
that they will be more bothersome to the patient.
This problem affects about 20–40% of patients suf-
fering from idiopathic urticaria. It is often referred
to as the urticaria/angioedema-type of aspirin hy-
persensitivity [9, 10]. The pathomechanism of aspi-
rin hypersensitivity that affects the skin is similar
to its bronchial form. It consists in the inhibition
of COX by aspirin and an increased synthesis of
cysteinyl leukotrienes [11, 12].
Very few reliable studies have been carried out
so far with regard to NSAIDs hypersensitivity in
patients with bronchial asthma [13, 14]. In the
European surveys ECRHS and ISAAC [15–22] the
symptoms of drugs hypersensitivity, in particular
intolerance to NSAIDs, are not taken into account.
Our knowledge about the frequency of aspirin-in-
duced asthma occurrence is based upon studies
conducted on select populations, e.g. groups of
patients with heavy asthma and disease exacerba-
tion requiring hospital treatment and/or mechani-
cal ventilation [23–25].
Between 1998 and 2000 a multicenter epide-
miological survey was carried out which focused
on the occurrence of allergic disease in Poland [26,
27]. The survey estimated the occurrence frequen-
cy of asthma, seasonal and perennial allergic rhi-
nitis as well as atopic dermatitis. The project also
took into consideration the assessment of drug
hypersensitivity symptoms, based on a question-
naire prepared by the Department of Medicine,
Jagiellonian University Medical College in Krakow.
The study aimed at a retrospective analysis of
epidemiological data on the occurrence frequency
of non-steroidal anti-inflammatory drugs hyper-
sensitivity in asthma patients. The data was gathe-
red in the period 1998–2000.
Material and methods
The epidemiological study related to the oc-
currence of asthma, seasonal and perennial rhini-
tis, as well as atopic and contact dermatitis, was
carried out in 11 Polish research centers (in Bialy-
stok, Bydgoszcz, Krakow, Gdansk, Lublin, Lodz,
Poznan, Rabka, Warsaw, Wroclaw and Zabrze). It
utilised a questionnaire on hypersensitivity to aspi-
rin and other non-steroidal anti-inflammatory
drugs. The document was drafted on the initiative
of the Department of Medicine, Jagiellonian Uni-
versity Medical College, which also contributed
greatly to its development. The detailed question-
naire contained five questions on hypersensitivi-
ty to aspirin and other non-steroidal anti-inflam-
matory drugs. If the respondents confirmed the
occurrence of any post-drug symptoms, they were
asked to specify the medicine by choosing from the
15 commonest drugs on the market, and to optio-
nally give its name. Further questions detailed the
symptoms which followed taking the medication:
dyspnea, whizzing, blocked nose with watery na-
sal secretion, skin symptoms, gastrointestinal tract
symptoms and anaphylactic shock symptoms. Then
the respondents were asked about the time of the
symptoms’ occurrence and whether they took the
same drug again later on and experienced a similar
sequence of symptoms. By collecting data from
16 238 people, including 12 970 adults, the centers
reached 98% of the planned number of respondents.
After obtaining consent from the Main Pro-
ject Coordinator in Wroclaw center, and from all
the researchers working in the other ten centers,
104 questionnaires were taken from the database.
This data concerned patients whom experts found
to be suffering from bronchial asthma and who
gave a positive answer to at least one question
on hypersensitivity to aspirin and non-steroidal
anti-inflammatory drugs.
Then a full epidemiological questionnaire stu-
dy was conducted, focusing on patients suspected
of intolerance to anti-inflammatory drugs. The stu-
dy covered nine of the 11 research centers partici-
pating in the project (one center did not obtain
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consent for using the survey materials, while in
another one the questionnaires were by accident
unavailable). Eventually, 75 questionnaires were
included in the analysis. Due to the fact that many
patients living in distant parts of Poland could not
and/or did not want to visit the Department of
Medicine in Krakow to perform aspirin challenge
tests, the verification of diagnosed aspirin-induced
asthma and other types of hypersensitivity reac-
tions was mainly based on detailed history of the
patients, the type of drugs taken by them and ana-
lysis of patients’ medical documentation. In the
Krakow center itself, suspected diagnosis of aspi-
rin-induced asthma was mostly confirmed by me-
ans of an aspirin challenge test.
To identify the group of patients with NSAID
hypersensitivity, and to compare the severity of
asthma, the study involved a group of patients
showing good tolerance to apirin. This group was
selected in the same epidemiological study car-
ried out in the Krakow center. In view of the availa-
bility of epidemiological questionnaires in Kra-
kow, patients from this center were qualified for
inclusion in the statistical analysis.
The analysis was carried out using StatisticaTM
PL software. The groups studied were characterized
using descriptive statistics. The occurrence frequen-
cy of allergic diseases as well as 95% confidence
intervals were calculated. Variability within the
groups was compared using a t-Student test for in-
dependent variables and chi-square test. The mul-
tiple factor statistical analysis of bronchial asthma
gravity in various subgroups was carried out using
the logistic regression method. The significance le-
vel assumed for the calculation was a = 0.05.
Results
According to the data published by the re-
search team from Wroclaw (37), the frequency of
asthma occurrence equals 5.4%. This precisely
matches our calculations based on the results from
nine centers, which were included in the statisti-
cal analyses of hypersensitivity reactions to non-
-steroidal anti-inflammatory drugs. The represen-
tative population from the nine centers amounted
to 10 684 adults. The epidemiological history ta-
king allowed for diagnosing bronchial asthma in
582 persons. From this group 75 patients, i.e. 12.9%
of the total population studied, additionally repor-
ted the symptoms of hypersensitivity to non-ste-
roidal drugs and aspirin.
The distribution analysis of answers to ques-
tions on hypersensitivity symptoms showed that
most reactions, 60% to be exact, were related to
the skin. Skin manifestation of hypersensitivity
was the only symptom reported in 25 patients,
i.e. 33.3% of the studied group. In the remaining
50 patients, skin manifestations were accompa-
nied by other symptoms such as dyspnea, na-
sal and abdominal reactions, and general col-
lapse. The second most frequent hypersensiti-
vity reaction was manifestation related to the
gastrointestinal tract. Symptoms such as the
occurrence of abdominal pain and/or diarrhoea
after taking NSAIDs were reported by 28 patients
(37.3%). In 12 people (16%) from the group this
was the only drug-related reaction. Thirteen asth-
ma patients (17.3%) reported in their medical hi-
story that after using non-steroidal anti-inflamma-
tory drugs they experienced a shock, defined as
significant asthenia and loss of consciousness.
Following the verification of 18 patients (24%)
who reported dyspnea and ten patients with nasal
symptoms (13.3%), aspirin-induced asthma was
eventually recognised in 11 patients, i.e. 14.7% of
the group showing clinical manifestations of hy-
persensitivity reactions. Figure 1 presents these
reactions in a graphic form.
Dyspnea in the remaining patients was as-
sociated with other hypersensitivity reactions,
especially the ones affecting upper airways.
These symptoms took the form of angioedema or,
in some patients, a general systemic reaction
(shock). A single nasal reaction without dyspnea
occurred in two patients (2.7%).
Aspirin-induced asthma is a form of severe,
chronic asthma. In our study the occurrence fre-
quency of aspirin-induced asthma with clinical
symptoms amounted to 1.9% of the asthma pa-
tients. The frequency of aspirin-induced asthma in
the whole adult population covered by the Polish
study equals 0.1%. Figures 2 and 3 show these re-
sults in graphic form.
Neither group of asthma patients: the study
group (75 people) and controls without any hyper-
sensitivity reactions (72 people), differed statisti-
cally with regard to number or age. The average
age in the group of patients with NSAID hypersen-
sitivity was 44.7 ± 14.9 years, whereas in the con-
trol group it was 44.3 ± 16.5. In both populations
studied there were significantly more women,
who prevailed particularly in the hypersensitivity
group (73.3% and 61.1%, respectively). In the chi-
-square test no statistically significant differences
were found in the age structure of both groups.
These groups were also similar with regard to the
duration of the disease (11.7 ± 9.6 years in the hy-
persensitivity patients vs. 14.0 ± 14.4 years in the
control group), and the percentage of cigarette
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Figure 1. The prevalence of reactions after NSAIDs among asthmatics (n = 75)
Figure 2. The frequency of asthma  and aspirin induced asthma in the population of adults in Poland
Figure 3. The frequency of any kind of hypersensitivity to nonsteroid anti-inflammatory drugs (NSAIDs)
(with aspirin induced asthma) and aspirin induced asthma among asthmatics
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Table 1. Characteristic of study subgroups
Patients with symptoms of Patients without symptoms of Statistic significance
hypersensitivity to NSAIDs  hypersensitivity to NSAIDs p
(n = 75) (control group; n =72)
c ± SD (min, max) c ± SD (min, max)
Age (years) 44.7 ± 14.9 44.3 ± 16.5 0.9
(18, 79) (17, 79)
Duration of disease (years) n = 65* n = 62* 0.29
11.7 ± 9.6 14.0 ± 14.4
(0. 45) (0. 52)
Gender (female/male) 55/20 44/28 0.11
73.3%/26.7% 61.1%/38.9%
Smoking status 44 (58.7%) 34 (47.2%) 0.16
*Diagnosed patients
smokers (58.7% vs. 47.2%). The demographic
data are presented in Table 1.
Although the control group was not representa-
tive nationwide, both populations (the study group
and controls from Krakow) have been selected cor-
rectly with regard to their size (75 and 72 people,
respectively), sex structure, cigarette smoking and
duration of the disease.
Table 2 contains clinical characteristics of
bronchial asthma in both groups.
In the NSAID hypersensitivity group, accor-
ding to the GINA guidelines, moderate-persistent
asthma and severe-persistent asthma could be re-
cognised in 21.3% of patients. In the control group
without hypersensitivity, this percentage amoun-
ted to 9.7%. The difference observed verges upon
statistical significance (p = 0.052). Figure 4 shows
the percentage of severe asthma in every subgro-
up of the populations covered by the study.
The assessment of disease severity must also
take into account anti-asthmatic treatment. Table 2
compares drugs used by the patients in both groups.
The group of patients with hypersensitivity to
non-steroidal anti-inflammatory drugs, including
Table 2. Clinical characteristics of asthmatics in study subgroups
Patients with symptoms of Patients without symptoms of Statistic significance
hypersensitivity to NSAIDs  hypersensitivity to NSAIDs p
(n = 75) (control group; n =72)
c ± SD (min, max) c ± SD (min, max)
Duration of disease (years) n = 65* n = 62* 0.29
11.7 ± 9.6 14.0 ± 14.4
(0, 45) (0, 52)
Severity of disease
episodic + mild 59 (78.7%) 65 (90.3%) 0.052 (chi2)
moderate + severe 16 (21.3%) 7 (9.7%)
Antiasthmatic treatment 41 (54.7%) 20 (27.8%) 0.0009
Beta-mimetics 32 (42.7%) 16 (22.2%) 0.86
Anticholinergic drugs 9 (12.0%) 6 (8.3%) 0.49
Inhaled steroids 15 (20.0%) 10 (13.9%) 0.32
Systemic steroids 12 (16.0%) 6 (8.3%) 0.95
Intravenous steroids 14 (18.7%) 3 (4.2%) 0.12
Theophylline 26 (34.7%) 11 (15.3%) 0.53
Cromons 15 (20.0%) 10 (13.9%) 0.32
Asthma attack during last year 27 (36%) 18 (25%) 0.92
*Diagnosed patients
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the people with aspirin-induced asthma, used
anti-asthmatic treatment statistically much more
frequently (p = 0.0009; assuming 95% confiden-
ce interval the odds ratio is 3.14) for better control
of the symptoms. The analysis of anti-asthmatic
drug groups revealed no statistical significance.
It should be stressed, however, that in the group
of patients with aspirin-induced asthma, 45.5%
(five out of 11 people) required the intravenous ad-
ministration of glycocorticosteroids during disease
exacerbation, which in a way shows the severity
of dyspnea attacks they experienced.
For statistical analyses we used the logistic
regression model, where severity of asthma (both
moderate-persistent and severe-persistent) was
a dependent variable, whereas age, gender, di-
sease duration, tobacco smoking and drug hyper-
sensitivity were independent variables. Statisti-
cally significant results were obtained only with
relation to the patients’ age and drug hypersen-
sitivity. Following the elimination of cigarette
smoking, statistically significant results were
obtained only with relation to the patients’ age
(p = 0.03; assuming 95% confidence interval the
odds ratio was 1.04) and hypersensitivity to cyclo-
oxygenase inhibitors (p = 0.04; assuming 95%
confidence interval the odds ratio was 2.9). The-
se conclusions were confirmed by further sta-
tistical analyses. In the logistic regression
model used to assess the disease severity in the
study group (n = 75), the diagnosis of aspirin-in-
duced asthma was included as a dependent va-
riable, together with age, gender, disease dura-
tion and tobacco smoking. No statistically signi-
ficant results were obtained in this case with
regard to gender, disease duration, cigarette
smoking or patients’ age. Only aspirin intoleran-
ce has a significant bearing upon asthma severi-
ty (p = 0.0003; assuming 95% confidence inter-
val the odds ratio was 28.6).
Discussion
This epidemiological study on the frequen-
cy of allergy disease occurrence in Poland was
conducted in 1998–2000. It was the first large-
scale epidemiological study of the Polish popu-
lation to be carried out using correct and accu-
rate scientific methods. The study encompassed
10 000 adults and children, and covered the
whole of Poland. In order to achieve the most pre-
cise assessment of the frequency of allergic di-
sease occurrence, the project required immen-
se workload related to the execution of the stu-
dy protocol.
No studies on hypersensitivity reactions to
non-steroidal anti-inflammatory drugs have been
conducted so far in Poland. Neither has this pro-
blem been studied in asthma patients. It should be
noted that asthma patients are particularly vul-
Figure 4. Severity of persistent asthma in subgroups of patients
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nerable due to the possibility of disease exacer-
bation, or even death, caused by the use of aspi-
rin and NSAIDs [24, 25].
In our study, hypersensitivity reactions to
NSAIDs appeared in 12.9% of bronchial asthma
patients. The most frequent symptom of NSAID
hypersensitivity was the skin manifestation. Such
a single hypersensitivity reaction was reported as
the only symptom by 33% of patients. In 60% of
patients it was accompanied by other symptoms.
In our study the skin changes were analysed join-
tly, without distinction into oedema and urticaria.
Similar results were obtained by Schubert et al.
[28]. Their study was based on a preliminary anam-
nesis of 260 people who underwent a challenge test
to check the diagnosis of hypersensitivity to non-
-steroid drugs. It was discovered that hypersen-
sitivity was not confirmed in almost half the po-
pulation participating in the German study.
Our data also corresponds with a Turkish stu-
dy. Kalyoncu et al. [29] found that in a group of
132 patients with drug hypersensitivity diagnosed
in their medical history, 28% had skin manifesta-
tions in the form of persistent urticaria, whereas
24.2% of bronchial asthma patients suffered from
oedemic skin changes. A similar percentage of pe-
ople (2.4% in the Turkish study vs. 2.7% in the
Polish study) experienced a single reaction affec-
ting the nasal mucosa. When compared to the Tur-
kish study, which reported anaphylactic shock
reactions in 6.8% of bronchial asthma patients, we
have noted twice as many similar reactions: 17.3%.
In the German study Schubert [28] reported only
3.5% systemic reactions.
In our opinion, the relatively high percenta-
ge of gastrointestinal tract reactions (37.3%, and
16% of cases as a single reaction) contradicts the
findings of the Turkish study, which reported an
abdominal manifestation in just one patient (0.8%).
This disparity might result from misunderstan-
ding of the question by some respondents. In the ques-
tionnaire we asked about reactions related to the
gastrointestinal tract („stomach ache and diarrho-
ea”). There is some likelihood that while answe-
ring this question, the respondents took into acco-
unt only its first part, i.e. abdominal pain. We know,
however, that dyspeptic symptoms or even ulce-
rous disease are quite frequent and sometimes life-
-threatening side-effects of persistent use of non-ste-
roidal anti-inflammatory drugs. Ulceration of ga-
strointestinal tract mucosa and all the related
complications occur in ca. 25% of patients taking
NSAIDs [30–32]. Peura [33] reports that the fre-
quency of dyspeptic symptoms occurrence in people
using these kinds of drugs amounts to as much as
50%. Given this, we cannot rule out that reactions
reported by the patients in our study could be lin-
ked to such symptoms, thus leading to slightly
higher results.
In the paper we presented the frequency of
aspirin-induced asthma occurrence in Poland. It
equals 1.9% of bronchial asthma patients, or 0.1%
of the adult population. Study results published
in 2003 [34] indicated a higher aspirin-induced
asthma frequency, which amounted to 4.3%. This
significant (almost 50%) difference in the frequen-
cy of aspirin-induced asthma is attributable to our
detailed verification of epidemiological diagnoses.
The challenge tests performed in Krakow confir-
med hypersensitivity in 75% of cases (i.e. three in
every four patients who agreed to participate in this
study). Due to the fact that many patients living in
distant parts of Poland could not and/or did not want
to visit the Department of Medicine in Krakow to
undergo the aspirin challenge tests, the verification
of diagnoses was mainly based on detailed history
of the patients, the type of drugs taken by them and
the analysis of patients’ medical documentation. In
the later part of the assessment, we found that six
patients tolerate NSAIDs well; in another seven
patients the diagnosis of asthma was not confirmed.
In other, earlier epidemiological studies, the repor-
ted occurrence of aspirin-induced asthma oscilla-
ted between 3% and 9% [35–37].
The analysis of our studies indicates that pa-
tients with drug hypersensitivity require a more
intense, statistically significant anti-asthmatic treat-
ment (p = 0.0009). However, no statistically si-
gnificant differences were found in the use of anti-
-asthmatic drugs. On the other hand, in the subgro-
up of 11 patients with diagnosed aspirin-induced
asthma, 45% used corticosteroids intravenously
during disease exacerbation, whereas there were
only 4% of such people in the control group. By
comparison, in the AIANE study [23] 25% of asth-
ma patients required intravenous injection of cor-
ticosteroids to stop an attack of dyspnea.
We agree with other authors in the observa-
tion that hypersensitivity to analgesics is a predis-
position to a more severe form of the disease [38].
As for disease severity, the comparison of the stu-
dy population with a control population revealed
that moderate and severe asthma occurred more
frequently in the group with hypersensitivity
symptoms. In the chi-square test this difference
verged upon statistical significance. The fact that
more drugs are used to better control the symptoms
in a way indicates the level of disease severity. By
analysing the effect of multiple factors on disease
severity, we proved, using the logistic regression
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model, that hypersensitivity to drugs triples the li-
kelihood of a more severe form of the disease. More-
over, using the same statistical model, we proved
that aspirin sensitivity combined with dyspnea
(aspirin-induced asthma) increases this risk almost
30 times. Also, the age of the people surveyed had
some influence on disease severity. The older the
patient, the more severe the disease.
Conclusions
The frequency of aspirin-induced asthma oc-
currence in the Polish adult population is 0.1%.
In the group of adult asthma patients, this frequen-
cy is 1.9%. Hypersensitivity reactions to non-
-steroidal anti-inflammatory drugs occur in 12.9%
of adult asthma patients in Poland. Patients with
aspirin-induced asthma have statistically signifi-
cant, more severe clinical course of the disease
when compared to aspirin-tolerant asthma pa-
tients. In the former group, the risk of severe asth-
ma is almost 30-fold higher.
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